Current Report · Items 2.02, 9.01 · 8-K

Geron Corporation

GERNNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Feb 26, 2025Accepted Feb 26, 2025, 7:45 AM ESTCIK 886744Accession 0000950170-25-027331

Company context

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. To learn more, visit www.geron.com or follow us on LinkedIn.

Current securities

GERNNASDAQ · EQUITY · Current

Historical securities (1)

GERNWNASDAQ · WARRANT · Historical · closed Dec 30, 2025

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition On February 26, 2025, Geron Corporation (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024 and recent business highlights. A copy of the press release is attached as Exhibit 99.1. The information contained in Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Filed exhibits (1)

EX-99.1 (by filename) gern-ex99_1.htm

EX-99.1 2 gern-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met FOSTER CITY, Calif., February 26, 2025 -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated treatment with blockbuster potential in the high unmet need, lower-risk MDS patient population. We also continued to progress our development efforts in relapsed/refractory myelofibrosis, which could potentially double our commercial opportunity if our IMpactMF Phase 3 trial reads out positiv…

Open exhibit ↗